Drugs / 177Lu-PSMA
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03874884 | Jul 2019 → May 2025 overdue | prostate carcinoma | Peter MacCallum Cancer Centre, Australia | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03658447 | Jul 2019 → Dec 2022 | castration-resistant prostate carcinoma | Peter MacCallum Cancer Centre, Australia | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05560659 | Dec 2023 → May 2026 overdue | metastatic prostate carcinoma | Peter MacCallum Cancer Centre, Australia | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 177Lu-PSMA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03658447 ↗ |
| Action | Inhibit | “a small molecule inhibitor of PSMA” NCT05560659 ↗ |
| Modality | Small molecule | “a small molecule inhibitor of PSMA” NCT05560659 ↗ |
| Route | Intravenous | “[177Lu]Lu-PSMA-617 intravenously every 6 weeks” PMID 41926961 ↗ Apr 2026 |